GlaxoSmithKline files its arguments to Supreme Court of Canada
GlaxoSmithKline (GSK) has filed its case facts with the Supreme Court of Canada refuting arguments made by the Crown in this precedent-setting transfer pricing case, involving the price of the active ingredient used to make the drug sold under the brand name Zantac.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: